Literature DB >> 23065528

Reference intervals for plasma free metanephrines with an age adjustment for normetanephrine for optimized laboratory testing of phaeochromocytoma.

Graeme Eisenhofer1, Peter Lattke, Maria Herberg, Gabriele Siegert, Nan Qin, Roland Därr, Jana Hoyer, Arno Villringer, Aleksander Prejbisz, Andrzej Januszewicz, Alan Remaley, Victoria Martucci, Karel Pacak, H Alec Ross, Fred C G J Sweep, Jacques W M Lenders.   

Abstract

BACKGROUND: Measurements of plasma normetanephrine and metanephrine provide a useful diagnostic test for phaeochromocytoma, but this depends on appropriate reference intervals. Upper cut-offs set too high compromise diagnostic sensitivity, whereas set too low, false-positives are a problem. This study aimed to establish optimal reference intervals for plasma normetanephrine and metanephrine.
METHODS: Blood samples were collected in the supine position from 1226 subjects, aged 5-84 y, including 116 children, 575 normotensive and hypertensive adults and 535 patients in whom phaeochromocytoma was ruled out. Reference intervals were examined according to age and gender. Various models were examined to optimize upper cut-offs according to estimates of diagnostic sensitivity and specificity in a separate validation group of 3888 patients tested for phaeochromocytoma, including 558 with confirmed disease.
RESULTS: Plasma metanephrine, but not normetanephrine, was higher (P < 0.001) in men than in women, but reference intervals did not differ. Age showed a positive relationship (P < 0.0001) with plasma normetanephrine and a weaker relationship (P = 0.021) with metanephrine. Upper cut-offs of reference intervals for normetanephrine increased from 0.47 nmol/L in children to 1.05 nmol/L in subjects over 60 y. A curvilinear model for age-adjusted compared with fixed upper cut-offs for normetanephrine, together with a higher cut-off for metanephrine (0.45 versus 0.32 nmol/L), resulted in a substantial gain in diagnostic specificity from 88.3% to 96.0% with minimal loss in diagnostic sensitivity from 93.9% to 93.6%.
CONCLUSIONS: These data establish age-adjusted cut-offs of reference intervals for plasma normetanephrine and optimized cut-offs for metanephrine useful for minimizing false-positive results.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23065528      PMCID: PMC4714582          DOI: 10.1258/acb.2012.012066

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  37 in total

1.  Nonparametric determination of reference intervals for plasma metanephrine and normetanephrine.

Authors:  Emily C Heider; Bret G Davis; Elizabeth L Frank
Journal:  Clin Chem       Date:  2004-12       Impact factor: 8.327

2.  False positive test results for pheochromocytoma from 2000 to 2008.

Authors:  R Yu; M Wei
Journal:  Exp Clin Endocrinol Diabetes       Date:  2009-12-08       Impact factor: 2.949

3.  Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2.

Authors:  G Eisenhofer; J W Lenders; W M Linehan; M M Walther; D S Goldstein; H R Keiser
Journal:  N Engl J Med       Date:  1999-06-17       Impact factor: 91.245

4.  Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine.

Authors:  Graeme Eisenhofer; David S Goldstein; Patricia Sullivan; Gyorgy Csako; Frederieke M Brouwers; Edwin W Lai; Karen T Adams; Karel Pacak
Journal:  J Clin Endocrinol Metab       Date:  2005-01-11       Impact factor: 5.958

5.  Plasma free metanephrine measurement using automated online solid-phase extraction HPLC tandem mass spectrometry.

Authors:  Wilhelmina H A de Jong; Kendon S Graham; Jan C van der Molen; Thera P Links; Michael R Morris; H Alec Ross; Elisabeth G E de Vries; Ido P Kema
Journal:  Clin Chem       Date:  2007-09       Impact factor: 8.327

6.  A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines.

Authors:  Anna M Sawka; Roman Jaeschke; Ravinder J Singh; William F Young
Journal:  J Clin Endocrinol Metab       Date:  2003-02       Impact factor: 5.958

7.  Measurement of plasma free metanephrine and normetanephrine by liquid chromatography-tandem mass spectrometry for diagnosis of pheochromocytoma.

Authors:  Susan A Lagerstedt; Dennis J O'Kane; Ravinder J Singh
Journal:  Clin Chem       Date:  2004-01-15       Impact factor: 8.327

8.  Free plasma metanephrines as a screening test for pheochromocytoma in low-risk patients.

Authors:  Jan Václavík; David Stejskal; Borek Lacnák; Marie Lazárová; Libor Jedelský; Lenka Kadalová; Marie Janosová; Zdenek Frysák; Petr Vlcek
Journal:  J Hypertens       Date:  2007-07       Impact factor: 4.844

9.  Determination of metanephrines in plasma by liquid chromatography with electrochemical detection.

Authors:  J W Lenders; G Eisenhofer; I Armando; H R Keiser; D S Goldstein; I J Kopin
Journal:  Clin Chem       Date:  1993-01       Impact factor: 8.327

10.  Plasma free metanephrines are superior to urine and plasma catecholamines and urine catecholamine metabolites for the investigation of phaeochromocytoma.

Authors:  Peter E Hickman; Michelle Leong; Julia Chang; Susan R Wilson; Brett McWhinney
Journal:  Pathology       Date:  2009-02       Impact factor: 5.306

View more
  14 in total

1.  Mass spectrometric quantification of salivary metanephrines-A study in healthy subjects.

Authors:  Thamara E Osinga; Anouk N A van der Horst-Schrivers; Martijn van Faassen; Michiel N Kerstens; Robin P F Dullaart; Karel Pacak; Thera P Links; Ido P Kema
Journal:  Clin Biochem       Date:  2016-02-10       Impact factor: 3.281

Review 2.  Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment.

Authors:  Victoria L Martucci; Karel Pacak
Journal:  Curr Probl Cancer       Date:  2014-01-15       Impact factor: 3.187

Review 3.  Recent Trends in the Quantification of Biogenic Amines in Biofluids as Biomarkers of Various Disorders: A Review.

Authors:  Alina Plenis; Ilona Olędzka; Piotr Kowalski; Natalia Miękus; Tomasz Bączek
Journal:  J Clin Med       Date:  2019-05-09       Impact factor: 4.241

4.  Adrenal medullary dysfunction as a feature of obesity.

Authors:  M Reimann; N Qin; M Gruber; S R Bornstein; C Kirschbaum; T Ziemssen; G Eisenhofer
Journal:  Int J Obes (Lond)       Date:  2017-02-06       Impact factor: 5.095

5.  The relationship between blood pressure variability and catecholamine metabolites: a pilot study.

Authors:  J M Coulson
Journal:  J Hum Hypertens       Date:  2014-04-03       Impact factor: 3.012

6.  Urinary and plasma catecholamines and metanephrines in dogs with pheochromocytoma, hypercortisolism, nonadrenal disease and in healthy dogs.

Authors:  E Salesov; F S Boretti; N S Sieber-Ruckstuhl; K M Rentsch; B Riond; R Hofmann-Lehmann; P R Kircher; E Grouzmann; C E Reusch
Journal:  J Vet Intern Med       Date:  2015 Mar-Apr       Impact factor: 3.333

Review 7.  Review of Pediatric Pheochromocytoma and Paraganglioma.

Authors:  Reshma Bholah; Timothy Edward Bunchman
Journal:  Front Pediatr       Date:  2017-07-13       Impact factor: 3.418

8.  A high rate of modestly elevated plasma normetanephrine in a population referred for suspected PPGL when measured in a seated position.

Authors:  Jessica Boyd; Alexander A Leung; Hossein Sm Sadrzadeh; Christina Pamporaki; Karel Pacak; Timo Deutschbein; Stephanie Fliedner; Gregory A Kline
Journal:  Eur J Endocrinol       Date:  2019-09       Impact factor: 6.664

Review 9.  Adrenal Incidentaloma.

Authors:  Mark Sherlock; Andrew Scarsbrook; Afroze Abbas; Sheila Fraser; Padiporn Limumpornpetch; Rosemary Dineen; Paul M Stewart
Journal:  Endocr Rev       Date:  2020-12-01       Impact factor: 19.871

10.  Diagnostic Accuracy of Salivary Metanephrines in Pheochromocytomas and Paragangliomas.

Authors:  Karin Eijkelenkamp; Thamara E Osinga; Martijn van Faassen; Ido P Kema; Michiel N Kerstens; Karel Pacak; Wim J Sluiter; Thera P Links; Anouk N A van der Horst-Schrivers
Journal:  Clin Chem       Date:  2021-08-05       Impact factor: 12.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.